Sentinel Lymph Node Biopsy Prior to Neoadjuvant Chemotherapy: A Series of 89 Patients

Flipo Bernard¹, Clough Krishna², Nos Claude³, Miramand Bernard⁴, Michel Cecile⁵, Houvenaeghel Gilles⁶, Meurette Jacques⁷, Alfonsi Jean-Pierre⁸

¹Breast Surgery Department, Centre Antoine Lacassagne, Nice, France; ²Clough Krishna, Institut du Sein, Paris, France; ³Nos Claude, Institut du Sein, Paris, France; ⁴Miramand Bernard, Polyclinique Urbain V, Avignon, France; ⁵Michel Cecile, Biostatistics Department, Centre Antoine Lacassagne, Nice, France; ⁶Houvenaeghel Gilles, Institut Paoli-Calmettes, Marseille, France; ⁷Meurette Jacques, Clinique Ste-Amé, Lambres lez Douai, France; ⁸Alfonsi Jean-Pierre, Clinique St. Antoine, Ville di Pietrabugno, France.

Email: bernard.flipo@nice.unicancer.fr

Received August 2nd, 2012; revised September 4th, 2012; accepted September 15th, 2012

ABSTRACT

Purpose: There are still un-responded questions concerning the type of and the timing of axillary procedures that has to be performed in association with neoadjuvant chemotherapy. Methods: We led a prospective, multicentric, non-randomized study to evaluate the feasibility and accuracy of sentinel lymph node biopsy before neoadjuvant chemotherapy. The clinical and radiological response to chemotherapy was evaluated after 4 treatment cycles and at the end of chemotherapy. Axillary lymph node dissection was performed 3 to 4 weeks after chemotherapy. Histological analysis of sentinel lymph node biopsies and axillary lymph node dissections were studied for each patient. Results: Eighty nine patients had sentinel lymph node biopsy. The identification rate for sentinel lymph nodes was 98.9%. The sentinel lymph node biopsies were metastatic in 44 of 88 patients. Axillary lymph nodes were metastatic in 12 cases. The negative predictive value was 91.1% [95%CI: 85.1% - 97.1%]. Conclusion: Identification rate and negative predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy confirm that the procedure is suitable with its use in standard practice. This approach comprises two surgical procedures, but allows a better nodal status evaluation.

Keywords: Breast Cancer; Neoadjuvant Therapy; Clinical Trial; Sentinel Lymph Node Biopsy

1. Introduction

The recourse to neoadjuvant chemotherapy (NC) has increased during the last years as it sometimes allows breast conservation and permits an evaluation of tumor response though providing prognostic information. However, even if the side effects of axillary dissection [1], as well as the benefits of Sentinel Lymph Node Biopsy (SLNB) are known [2], there are still un-responded questions concerning the type of and the timing of axillary procedures that has to be performed in association with NC [3]. A meta-analysis has shown that identification rates for SLNB after neoadjuvant chemotherapy, are suitable with its use in standard practice [4]. Moreover, Jones et al. and the meta-analysis of Iwase et al. found a significantly better identification rates when SLNB was performed before neoadjuvant chemotherapy (96% - 100% versus 71% - 98%), and though recommended the procedure before NC for clinically N0 patients [5,6]. Last, it may give data useful in guiding systemic [7], radiation and surgical treatment decisions. These elements led us to design a study consisting to a SLNB before NC and an axillary lymph node dissection (AD) after NC, in order to validate the feasibility, accuracy and to evaluate the interest of SLNB prior to neoadjuvant chemotherapy.

2. Patients and Methods

2.1. Study Design

We led a prospective, multicentric, non-randomized study. This study obtained authorization from French Health authorities. It was designed and conducted in accordance with Good Clinical Practice Guidelines and the latest revision of the declaration of Helsinki. The ethics committee (CPP Sud Mediterranee V) approved the study in April 2006. Before inclusion, all patients provided written informed consent.

2.2. Patients

The inclusion criteria retained were: age ≥18 and ≤70 years-old, histological proof of single, unilateral, T2 or
T3 invasive breast cancer according to AJCC classification [8] and/or tumor size not permitting breast conserva-
tive surgery, clinical and radiological N0. Exclusion cri-
teria included: distant metastasis, inflammatory breast
cancer, previous chemotherapy for contralateral breast
cancer, and allergy to Patent Blue dye.

2.3. Lymphatic Mapping of the Sentinel Node

All patients had preoperative periareolar or peritumoral
radiocolloid (99Technetium) and Patent Blue dye injec-
tion. A lymphoscintigraphy of the breast and the axilla
were performed to determine the position of the sentinel
node as described by Lelievre et al. [9].

2.4. Sentinel Lymph Node Biopsy

SLNB was performed at the time of chemotherapy-port
insertion under general anesthesia. All lymph nodes pre-
senting blue dye and/or radioactive counts were identi-
fied as sentinel lymph nodes, removed and sent individu-
ally for histological analysis with information concerning
blue dye uptake and ex-vivo radioactivity count.

2.5. Neoadjuvant Chemotherapy

All patients were assigned to receive 5-fluorouracil 500
mg/m², epirubicin 100 mg/m², and cyclophosphamide
500 mg/m² (FEC) intravenously on day 1 every 21 days
for 4 cycles followed by docetaxel 100 mg/m² intrave-
rously on day 1 every 21 days for an additional 4 cycles.
Human epidermal growth factor receptor 2 (Her2) posi-
tive patients also received trastuzumab concomitant to
docetaxel. The clinical and radiological responses to NC
were evaluated after 4 treatment cycles and at the end of
chemotherapy treatment.

In this study, clinical response was defined as: com-
plete response, no palpable tumor; partial response, re-
gression of ≥50% of tumor; stabilization, regression of
<50% of tumor or no change at all; progression, increase
of the tumor size.

2.6. Axillary Lymph Node Dissection and Breast
Surgery

Breast surgery was performed 3 to 4 weeks after the end
of neoadjuvant chemotherapy. The surgical procedures
comprised radical mastectomy or breast-conserving treat-
ment according to tumor response. Level I and II axillary
lymph node dissections were systematically performed.

2.7. Histology

Sentinel nodes were fixed with formalin, embedded in
paraffin, and analyzed by serial sectioning (200 μm),
stained with hematoxylin and eosin, and by immunohis-
tochemistry, if suspicious cells were found or if nodes
were negative. Axillary lymph node dissection and tumor
were examined according to standard procedures. The
histological response of the tumor and nodes was evalu-
ated by using Sataloff classification [10].

2.8. Statistical Analysis

The identification rate (IR) was defined as the proportion
of procedures in which a sentinel lymph node was suc-
cessfully identified.

The negative predictive value (NPV) was defined as
true negative (TN)/(TN + False Negative). In this setting,
a false-negative SLN could have resulted either from
misidentification of the SLN or from disease progression
under chemotherapy in 1 or more non-SLNs.

3. Results

3.1. Patients

From February 2006 to September 2009, 89 patients were
included at 11 centers. The mean age was 50.9 years
(range 28 - 77, SD = 10.6). Mean radiologic tumor size
was 3.1 centimeters (range 0.8 - 6.6, SD = 1.1). Patient
characteristics are described in Table 1.

3.2. Sentinel Lymph Node Biopsy

The identification rate for sentinel lymph node was
98.9% (88 out of 89 procedures). Blue dye and radio
colloids were used in combination in 77 patients (86.5%).
Five patients (5.6%) received only blue dye and 7 only
radio colloid (7.9%). The only patient for whom sentinel
lymph node identification failed had both blue dye and
radio colloids injections. The mean number of nodes re-
moved per procedure was 2.8 (range 1 - 9; SD 1.6). The
SLNB were metastatic in 44 of 88 patients (50%). Senti-
nel nodes were found in external mammary chain in 82
patients, in external and internal mammary chain in 3
patients, in internal mammary chain only, in 1 patient
and in other location in 1 patient.

3.3. Neoadjuvant Chemotherapy

The identification rate for sentinel lymph node was
98.9% (88 out of 89 procedures). Blue dye and radio
colloids were used in combination in 77 patients (86.5%).
Five patients (5.6%) received only blue dye and 7 only
radio colloid (7.9%). The only patient for whom sentinel
lymph node identification failed had both blue dye and
radio colloids injections. The mean number of nodes re-
moved per procedure was 2.8 (range 1 - 9; SD 1.6). The
SLNB were metastatic in 44 of 88 patients (50%). Senti-
nel nodes were found in external mammary chain in 82
patients, in external and internal mammary chain in 3
patients, in internal mammary chain only, in 1 patient
and in other location in 1 patient.

3.4. Surgical Procedure

Breast conservative procedure was performed in 65 pa-
Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th>Characteristics (89, 100%)</th>
<th>Number of patients (n)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median [range]</td>
<td>50</td>
<td>[28 - 77]</td>
</tr>
<tr>
<td>≤50</td>
<td>47</td>
<td>52.8%</td>
</tr>
<tr>
<td>&gt;50</td>
<td>42</td>
<td>47.2%</td>
</tr>
<tr>
<td>Tumor size’ (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median [range]</td>
<td>3.0</td>
<td>[0.8 - 6.6]</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cT2</td>
<td>75</td>
<td>84.3%</td>
</tr>
<tr>
<td>cT3</td>
<td>14</td>
<td>15.7%</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive ductal cancer</td>
<td>85</td>
<td>95.5%</td>
</tr>
<tr>
<td>Invasive lobular cancer</td>
<td>1</td>
<td>1.1%</td>
</tr>
<tr>
<td>Others</td>
<td>3</td>
<td>3.4%</td>
</tr>
<tr>
<td>Tumor grade (SBR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>9</td>
<td>10.1%</td>
</tr>
<tr>
<td>II</td>
<td>34</td>
<td>38.2%</td>
</tr>
<tr>
<td>III</td>
<td>40</td>
<td>44.9%</td>
</tr>
<tr>
<td>Unknown</td>
<td>6</td>
<td>6.7%</td>
</tr>
<tr>
<td>Hormonal receptor status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrogen-Receptor+</td>
<td>57</td>
<td>64.0%</td>
</tr>
<tr>
<td>Estrogen-Receptor−</td>
<td>30</td>
<td>33.7%</td>
</tr>
<tr>
<td>Estrogen-Receptor unknown</td>
<td>2</td>
<td>2.3%</td>
</tr>
<tr>
<td>Progesterone-Receptor+</td>
<td>45</td>
<td>50.6%</td>
</tr>
<tr>
<td>Progesterone-Receptor−</td>
<td>41</td>
<td>46.1%</td>
</tr>
<tr>
<td>Progesterone-Receptor unknown</td>
<td>3</td>
<td>3.3%</td>
</tr>
<tr>
<td>HER2 overexpression</td>
<td>26</td>
<td>29.2%</td>
</tr>
</tbody>
</table>

Table 2. Clinical and histological responses.

<table>
<thead>
<tr>
<th></th>
<th>NC complete (n = 83)</th>
<th>NC incomplete (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>21</td>
<td>-</td>
</tr>
<tr>
<td>Partial</td>
<td>55</td>
<td>2</td>
</tr>
<tr>
<td>Stabilization</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Progression</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Histological response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sataloff</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T-A</td>
<td>34</td>
<td>-</td>
</tr>
<tr>
<td>T-B</td>
<td>30</td>
<td>1</td>
</tr>
<tr>
<td>T-C</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>T-D</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Sataloff</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-A</td>
<td>46</td>
<td>1</td>
</tr>
<tr>
<td>N-B</td>
<td>25</td>
<td>5</td>
</tr>
<tr>
<td>N-C</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>N-D</td>
<td>4</td>
<td>-</td>
</tr>
</tbody>
</table>

NC: neoadjuvant chemotherapy.

Table 3. Concordance between histological analysis of SLNB before NC and axillary lymph node dissection after NC.

<table>
<thead>
<tr>
<th>AD results</th>
<th>Metastatic</th>
<th>Non metastatic</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLNB results</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>8 (18.2%)</td>
<td>36 (81.8%)</td>
<td>44</td>
</tr>
<tr>
<td>Non metastatic</td>
<td>4 (9.1%)</td>
<td>40 (90.9%)</td>
<td>1*</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>77</td>
<td>89</td>
</tr>
</tbody>
</table>

*1 non identified SLN; SLNB: sentinel lymph node biopsy; AD: axillary dissection.

Copyright © 2012 SciRes.

Patients (73%), while 24 (27%) patients had a radical mastectomy. All patients underwent AD. The mean number of nodes obtained per axillary dissection was 9.4 (range 1 - 37; SD = 4.4). Nodes were metastatic (either micro metastatic or macro metastatic) in 12 cases (13.5%). Among the 44 patients who had a metastatic SLNB, 8 had confirmed metastatic nodes on AD (Table 3). The negative predictive value was 91.1% [95% CI: 85.1% - 97.1%]. The nodes of the patient whose SLNB was not identified were not metastatic.

Four patients had a negative SLNB and a positive axillary dissection (9.1% of total negative SLNB). Two patients have over 50 years and two are under 50 years. The mean radiological tumor size was 1.7 centimeters (range 1.5 - 2.0). All patients presented an invasive ductal cancer and a cT2 clinical stage. Three out of four patients had a tumor grade II (SBR). Estrogen and progesterone receptor status were positive for 3 patients. Her2 status was negative for 3 out of 4 patients. Of note, one patient presented a triple-negative breast cancer. The mean number of SLN was 2.75% and 100% were localized in external mammary chain. All four patients received at least 6 chemotherapy treatment cycles. The residual tumor size ranged from 0 to 2.5 centimeters.

Eighty two percent of the patients who had a positive SLNB did not have any other metastatic node in the axil-
Sentinel lymph node biopsy in breast cancer is a highly sensitive technique for identifying axillary metastasis in a minimally invasive manner, compared to standard axillary dissection [11]. The use of this technique in association with NC is controversial and the optimal timing has not yet been precisely determined.

However, there are several arguments that are favorable to the use of SLNB prior to NC. A recent review article has shown that identification rates for SLNB prior to NC are suitable with its use in standard practice [12]. This is confirmed by our findings: the identification rate in our study reached 98.9%. Moreover, several studies have demonstrated an identification rates significantly better when SLNB was performed before neoadjuvant chemotherapy (96% to 100%) rather than after (71% to 98%), and though recommended the procedure before NC for clinically N0 patients [5,6]. The lower identification rate after NC could be related to chemotherapy-related fibrosis and tumor debris that change the lymphatic flow of the breast [12,13]. Moreover, if NC eradicates metastatic foci in SLNs but not in non-SLNs, false-negative results will eventually occur. However, in this setting in which axillary nodal status was affected by NC, a precise false-negative rate could not be calculated.

In our study, we should notice that among the 4 patients with negative SLN and positive AD, 2 showed progression of the disease under NC. Though, these 2 patients were not adequate for the SLNB evaluation prior to NC as the positive could be related to the progression of the disease. Moreover, the false negative rates of SNLB after NC found in the literature seem to be higher than those of SNLB prior to NC. In addition, considering the fact that nodal down staging occurs in 20% to 40% of cases after NC [14], the nodal status, which is a major prognosis parameter, might be distorted if explored after NC.

Last, knowing the nodal status is helpful when planning breast surgery as we might determine whether radiotherapy is required. This can affect the decision of achieving or postponing breast reconstruction when a mastectomy is planned.

Pre-NC evaluation of the nodal status goes along with the recent published data concerning SLNB. Indeed, Krag et al. have shown that patients with negative SLN that undergo chemotherapy do not benefit from complementary AD in terms of axillary recurrence or survival [15]. We might though be able to spare axillary lymph nodes in patients that have a negative pre-NC SLNB [3]. When the pre-NC SLNB is positive, it is still recommended to perform AD. However, there are few publications that propose a second SLNB [16], which could be done after NC. The “second SLNB” evaluation is in process and it cannot yet be recommended in common practice. Otherwise, Giuliano et al. have shown that patients with positive SLNB that undergo chemotherapy do not benefit from AD [17]. These findings, if confirmed by other studies, might lead to lymph node sparing even in patients with positive SLNB that undergo chemotherapy. As the evolution of axillary procedures seems to head toward SLNB without AD for a majority of patients, we do believe that having a non-distorted pre-NC nodal status is better for prognosis assessment.

However, several remarks have to be made. The rate of positive SLNB in our series is high (50%). This could be related to the fact that patients did not have ultrasound exploration of the axilla, which can help reducing the rate of positive SNLB [18]. We have though started systematic ultrasound exploration of the axilla prior to SLNB.

Moreover, our approach comprises two operations, before and after NC, while patients that undergo SLNB after NC sustain only one surgical procedure. Nevertheless, the SLNB was achieved at the time of chemotherapy-port insertion and the operating time was short as we did not have to wait for lymph node intra-operative histological examination.

5. Conclusion

This study evaluating nodal status for 89 patients before neoadjuvant chemotherapy constitutes the largest series of SLNB pre-NC. Our results seem to validate SNLB prior to NC by identification rate and negative predictive value suitable with its use in standard practice. Even if this approach comprises two surgical procedures, we do believe that it allows a better nodal status evaluation, as it is not distorted by chemotherapy. Basing our judgment on the results of the NSABP-B32 study [15], we could spare AD if the pre-NC SNLB is negative in patients who complete NC without disease progression.

6. Acknowledgements

This work was carried out with the participation of Dr. Monique Cohen, Dr. Jean-Claude Darmon, Dr. Sylvia Giard, Dr. Raoul Payan, Dr. Gérard Priou, Dr. Eric Wallégem, Dr. Ana Lorena Vasquez-Guerrero and Pr. Moïse Namer for the inclusion of patients.

This work was supported by Sanofi—Aventis and Cercle Sainte Agathe. ALVG’S participation is possible thanks to a grant received by CONACYT (National Council of Science and Technology, Mexico).

REFERENCES

Sentinel Lymph Node Biopsy Prior to Neoadjuvant Chemotherapy: A Series of 89 Patients


